Federal contract award
HDTRA118C0001
DEVELOP NOVEL AND INNOVATIVE SMALL MOLECULE THERAPEUTICS TO TREAT (POST-EXPOSURE THERAPEUTIC) INFECTIONS BY BOTH FILOVIRUS FAMILY MEMBERS (EBOLA VIRUSES AND MARBURG VIRUSES)
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Defense |
| Office | DCMA NORTHEAST |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AD92 — OTHER DEFENSE - APPLIED RESEARCH/EXPLORATORY DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $2.6M |
| Current contract value | $2.6M |
| Potential contract value / ceiling | $2.6M |
| Start date | Dec 15, 2017 |
| Current end date | Dec 14, 2018 |
| Potential end date | Dec 14, 2020 |
| Latest award activity | Dec 4, 2024 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Dec 4, 2024 | A00001 | $-40.1K | DEVELOP NOVEL AND INNOVATIVE SMALL MOLECULE THERAPEUTICS TO TREAT (POST-EXPOSURE THERAPEUTIC) INFECTIONS BY BOTH FILOVIRUS FAMILY MEMBERS (EBOLA VIRUSES AND MARBURG VIRUSES). |
Research next steps
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.